X4 Pharmaceuticals Inc. (XFOR) Insider Trading

Last 12 months

Insiders bought $12k and sold $463k on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Executive Chairman Adam R Craig sold $211k on Aug 12, 13% of their stake, outside a plan.

Net open-market

−$451k

1 buy · 5 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 3

executives and directors

Last open-market buy

Oct 2026

Oct 16, 2026

Get an email when XFOR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 16	Adam R Craig Executive Chairman	Bought	4,600	$2.58	$12k	1.4%	Form 4
Oct 1	David Kirske Chief Financial Officer	SoldNo plan	11,767	$2.86	$34k	7.0%	Form 4
Aug 12	John Volpone President	SoldNo plan	24,576	$4.44	$109k	8.5%	Form 4
Aug 12	Adam R Craig Executive Chairman	SoldNo plan	47,436	$4.44	$211k	13%	Form 4
Jun 30	David Kirske Chief Financial Officer	SoldNo plan	8,543	$4.26	$36k	4.8%	Form 4
May 12	David Kirske Chief Financial Officer	SoldNo plan	16,961	$4.29	$73k	8.8%	Form 4
Oct 23, 2025	Adam R Craig Executive Chairman	Bought	86,206	$2.90	$250k	30%	Form 4
Jan 24, 2025	Paula Ragan President and CEO	Sold10b5-1 plan	76,473	$0.45	$34k	6.6%	Form 4
Jan 24, 2025	Adam S. Mostafa Chief Financial Officer	Sold10b5-1 plan	74,773	$0.45	$34k	100%	Form 4
Jan 24, 2025	Mark Baldry Chief Commercial Officer	Sold10b5-1 plan	29,159	$0.45	$13k	24%	Form 4
Jan 24, 2025	Mary Dibiase Chief Operating Officer	Sold10b5-1 plan	22,258	$0.45	$10k	4.3%	Form 4
Jan 24, 2025	Christophe Arbet-Engels Chief Medical Officer	Sold10b5-1 plan	11,624	$0.45	$5k	45%	Form 4
Nov 15, 2024	Mark Baldry Chief Commercial Officer	Bought	13,404	$0.34	$5k	1.9%	Form 4
Nov 15, 2024	Paula Ragan President and CEO	Sold10b5-1 plan	31,897	$0.39	$12k	3.1%	Form 4

Oct 16
Adam R Craig
Executive Chairman · bought 4,600 at $2.58
$12k
1.4% of stake
Oct 1No plan
David Kirske
Chief Financial Officer · sold 11,767 at $2.86
$34k
7.0% of stake
Aug 12No plan
John Volpone
President · sold 24,576 at $4.44
$109k
8.5% of stake
Aug 12No plan
Adam R Craig
Executive Chairman · sold 47,436 at $4.44
$211k
13% of stake
Jun 30No plan
David Kirske
Chief Financial Officer · sold 8,543 at $4.26
$36k
4.8% of stake
May 12No plan
David Kirske
Chief Financial Officer · sold 16,961 at $4.29
$73k
8.8% of stake
Oct 23, 2025
Adam R Craig
Executive Chairman · bought 86,206 at $2.90
$250k
30% of stake
Jan 24, 202510b5-1 plan
Paula Ragan
President and CEO · sold 76,473 at $0.45
$34k
6.6% of stake
Jan 24, 202510b5-1 plan
Adam S. Mostafa
Chief Financial Officer · sold 74,773 at $0.45
$34k
100% of stake
Jan 24, 202510b5-1 plan
Mark Baldry
Chief Commercial Officer · sold 29,159 at $0.45
$13k
24% of stake
Jan 24, 202510b5-1 plan
Mary Dibiase
Chief Operating Officer · sold 22,258 at $0.45
$10k
4.3% of stake
Jan 24, 202510b5-1 plan
Christophe Arbet-Engels
Chief Medical Officer · sold 11,624 at $0.45
$5k
45% of stake
Nov 15, 2024
Mark Baldry
Chief Commercial Officer · bought 13,404 at $0.34
$5k
1.9% of stake
Nov 15, 202410b5-1 plan
Paula Ragan
President and CEO · sold 31,897 at $0.39
$12k
3.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch XFOR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

TCRXTScan Therapeutics Inc.

SRZNSurrozen, Inc.

TSHATaysha Gene Therapies Inc.

CRISCuris Inc.

ZEOXZeo Scientifix Inc.

RLAYRelay Therapeutics Inc.

ACOGAlpha Cognition Inc.

CRBUCaribou Biosciences, Inc.

Spot a number that looks wrong? Check it in XFOR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing XFOR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.